Ultragenyx Pharmaceutical (RARE) Change in Cash (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Change in Cash data on file, last reported at -$247.0 million in Q1 2026.

• On a quarterly basis, Change in Cash fell 448.89% year-over-year to -$247.0 million in Q1 2026; TTM through Mar 2026 was $50.0 million, a 193.62% increase from a year earlier, with the FY2025 full-year figure at $252.0 million, up 820.0% from the prior year.
• Change in Cash for Q1 2026 stood at -$247.0 million, down from $221.5 million in the prior quarter.
• Over the last five years, Change in Cash for RARE reached as high as $367.9 million in Q2 2024 and fell as low as -$330.0 million in Q3 2024.
• Historically, Change in Cash has averaged -$7.1 million across 5 years, with a median of $6.5 million in 2022.
• On a YoY basis, Change in Cash climbed as much as 2179.24% in 2024 and fell as far as 1035.71% in 2024.
• Year by year, Change in Cash stood at -$258.7 million in 2022, then soared by 154.11% to $140.0 million in 2023, then tumbled by 82.72% to $24.2 million in 2024, then jumped by 815.69% to $221.5 million in 2025, then slumped by 211.53% to -$247.0 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were -$247.0 million in Q1 2026, $221.5 million in Q4 2025, and $26.1 million in Q3 2025.